1
|
Craig RA, De Vicente J, Estrada AA, Feng JA, Lexa KW, Canet MJ, Dowdle WE, Erickson RI, Flores BN, Haddick PCG, Kane LA, Lewcock JW, Moerke NJ, Poda SB, Sweeney Z, Takahashi RH, Tong V, Wang J, Yulyaningsih E, Solanoy H, Scearce-Levie K, Sanchez PE, Tang L, Xu M, Zhang R, Osipov M. Discovery of DNL343: A Potent, Selective, and Brain-Penetrant eIF2B Activator Designed for the Treatment of Neurodegenerative Diseases. J Med Chem 2024; 67:5758-5782. [PMID: 38511649 DOI: 10.1021/acs.jmedchem.3c02422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2024]
Abstract
Eukaryotic translation initiation factor 2B (eIF2B) is a key component of the integrated stress response (ISR), which regulates protein synthesis and stress granule formation in response to cellular insult. Modulation of the ISR has been proposed as a therapeutic strategy for treatment of neurodegenerative diseases such as vanishing white matter (VWM) disease and amyotrophic lateral sclerosis (ALS) based on its ability to improve cellular homeostasis and prevent neuronal degeneration. Herein, we report the small-molecule discovery campaign that identified potent, selective, and CNS-penetrant eIF2B activators using both structure- and ligand-based drug design. These discovery efforts culminated in the identification of DNL343, which demonstrated a desirable preclinical drug profile, including a long half-life and high oral bioavailability across preclinical species. DNL343 was progressed into clinical studies and is currently undergoing evaluation in late-stage clinical trials for ALS.
Collapse
Affiliation(s)
- Robert A Craig
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Javier De Vicente
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Anthony A Estrada
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Jianwen A Feng
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Katrina W Lexa
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Mark J Canet
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - William E Dowdle
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Rebecca I Erickson
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Brittany N Flores
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Patrick C G Haddick
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Lesley A Kane
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Joseph W Lewcock
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Nathan J Moerke
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Suresh B Poda
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Zachary Sweeney
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Ryan H Takahashi
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Vincent Tong
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Jing Wang
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Ernie Yulyaningsih
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Hilda Solanoy
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | | | - Pascal E Sanchez
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| | - Liwei Tang
- Department of Chemistry, WuXi AppTec Co., Ltd., Tianjin 300457, China
| | - Musheng Xu
- Department of Chemistry, WuXi AppTec Co., Ltd., Tianjin 300457, China
| | - Rui Zhang
- Department of Chemistry, WuXi AppTec Co., Ltd., Tianjin 300457, China
| | - Maksim Osipov
- Denali Therapeutics Inc., South San Francisco, California 94080, United States
| |
Collapse
|
2
|
Chapelin F, Gedaly R, Sweeney Z, Gossett LJ. Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer. Mol Imaging Biol 2021; 24:208-219. [PMID: 34708396 DOI: 10.1007/s11307-021-01648-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 08/27/2021] [Accepted: 08/30/2021] [Indexed: 11/24/2022]
Abstract
Hypoxia is a key prognostic indicator in most solid tumors, as it is correlated to tumor angiogenesis, metastasis, recurrence, and response to therapy. Accurate measurement and mapping of tumor oxygenation profile and changes upon intervention could facilitate disease progression assessment and assist in treatment planning. Currently, no gold standard exists for non-invasive spatiotemporal measurement of hypoxia. Magnetic resonance imaging (MRI) represents an attractive option as it is a clinically available and non-ionizing imaging modality. Specifically, perfluorocarbon (PFC) beacons can be externally introduced into the tumor tissue and the linear dependence of their spin-lattice relaxation rate (R1) on the local partial pressure of oxygen (pO2) exploited for real-time tissue oxygenation monitoring in vivo. In this review, we will focus on early studies and recent developments of fluorine-19 MRI and spectroscopy (MRS) for evaluation of tumor oximetry and response to therapy.
Collapse
Affiliation(s)
- Fanny Chapelin
- F. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, 514F RMB, 143 Graham Avenue, Lexington, KY, USA. .,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
| | - Roberto Gedaly
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, USA.,Department of Surgery, Transplant Division, University of Kentucky, Lexington, KY, USA
| | - Zachary Sweeney
- College of Medicine, University of Kentucky, Lexington, KY, USA
| | - Liza J Gossett
- F. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, 514F RMB, 143 Graham Avenue, Lexington, KY, USA
| |
Collapse
|
3
|
Xu H, Clairfeuille T, Jao CC, Ho H, Sweeney Z, Payandeh J, Koth CM. A Flexible and Scalable High-Throughput Platform for Recombinant Membrane Protein Production. Methods Mol Biol 2019; 2025:389-402. [PMID: 31267463 DOI: 10.1007/978-1-4939-9624-7_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Integral membrane proteins (MP) are implicated in many disease processes and are the primary targets of numerous marketed drugs. Despite recent advances in the areas of MP solubilization, stabilization, and reconstitution, it remains a time-consuming task to identify the combination of constructs and purification conditions that will enable MP structure-function studies outside of the lipid bilayer. In this chapter, we describe a strategy for rapidly identifying and optimizing the solubilization and purification conditions for nearly any recombinant MP, based on the use of a noninvasive fluorescent probe (His-Glow) that specifically binds to the common hexahistidine affinity tag of expressed targets. This His-Glow approach permits fluorescent size-exclusion chromatography (FSEC) without the need for green fluorescent protein (GFP) fusion. A two-stage detergent screening strategy is employed at the solubilization stage, whereby appropriate detergent families are identified first, followed by optimization within these families. Screening up to 96 unique combinations of solubilization conditions and constructs can be achieved in less than 24 h. At the outset of each new project, we screen six different detergents for each construct and the subsequent implementation of a simple thermostability challenge further aids in the identification of constructs and conditions suitable for large-scale production. Our strategy streamlines the parallel optimization of appropriate production conditions for multiple MP targets to rapidly enable downstream biochemical, immunization, or structural studies.
Collapse
Affiliation(s)
- Hui Xu
- Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA
| | - Thomas Clairfeuille
- Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA
| | - Christine C Jao
- Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA
| | - Hoangdung Ho
- Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA
| | - Zachary Sweeney
- Department of Discovery Chemistry, Genentech Inc., South San Francisco, CA, USA
- Denali Therapeutics, South San Francisco, CA, USA
| | - Jian Payandeh
- Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA.
| | - Christopher M Koth
- Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA.
| |
Collapse
|
4
|
Reif K, Shen F, Wang Y, Huang T, Lin Z, Zhang J, Suto E, Kaplan C, Liao C, King B, Nguyen A, Yeh S, Delarosa D, Liimatta M, Chiu H, Sweeney Z, Safina B, Johnson A, DeMartino J, DeForge L, Salphati L, Lee W, Balazs M, Sutherlin D. Specific targeting of PI 3-kinase p110δ for the treatment of rheumatoid arthritis (P5177). The Journal of Immunology 2013. [DOI: 10.4049/jimmunol.190.supp.68.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
The p110δ isoform of PI3K is a therapeutic target for rheumatoid arthritis, but the cellular and molecular mechanisms by which PI3K mediates inflammation are poorly understood. Here we describe a novel highly selective p110δ small molecule inhibitor, G-286, that allowed dissecting the contribution specifically of p110δ to cellular pathways that are implicated in arthritis disease pathogenesis in human and mice. Using G-286, we demonstrate that p110δ regulates B cell- but not myeloid-cell dependent inflammatory arthritis in mice. G-286 blocks B cell receptor dependent proliferation and reduces autoantibody levels in collagen-induced arthritis abrogating disease. However, G-286 does not significantly inhibit FcγR-mediated inflammatory cytokine production in murine macrophages. Accordingly, selective p110δ inhibition did not significantly affect disease progression in FcγR- and myeloid cell-dependent autoantibody-induced arthritis. Importantly, we provide evidence that human and mice diverge in their relative dependency on p110δ to regulate FcγR responses. In addition to B cells and myeloid cells, T cells and osteoclasts contribute to rheumatoid arthritis pathogenesis. Utilizing G-286, we dissect the relative impact of p110δ inhibition on human and mouse T cell and osteoclast function. These results provide new insight in the role of p110δ in arthritis disease processes and offer a compelling rationale for targeting p110δ for the treatment of human rheumatoid arthritis.
Collapse
Affiliation(s)
- Karin Reif
- 1Immunology, Genentech, South San Francisco, CA
| | - Fang Shen
- 1Immunology, Genentech, South San Francisco, CA
| | - Yugang Wang
- 1Immunology, Genentech, South San Francisco, CA
| | - Tao Huang
- 1Immunology, Genentech, South San Francisco, CA
| | | | - Juan Zhang
- 1Immunology, Genentech, South San Francisco, CA
| | - Eric Suto
- 1Immunology, Genentech, South San Francisco, CA
| | | | - Cheng Liao
- 2Inflammation, Hoffmann-la-Roche, Nutley, NJ
| | | | | | - Sherry Yeh
- 1Immunology, Genentech, South San Francisco, CA
| | | | | | - Henry Chiu
- 1Immunology, Genentech, South San Francisco, CA
| | | | | | | | | | | | | | - Wyne Lee
- 1Immunology, Genentech, South San Francisco, CA
| | | | | |
Collapse
|